Table of Contents

• What is BIIB122?
• How BIIB122 Works
• Clinical Trials
• Eligibility Criteria
• Potential Benefits
• Safety and Side Effects
• Future Prospects

What is BIIB122?

BIIB122, also known as DNL151, is a new medication being developed to treat Parkinson’s disease^[1]. Parkinson’s disease is a progressive neurological disorder that affects movement, causing symptoms like tremors, stiffness, and difficulty with balance and coordination. BIIB122 is currently undergoing clinical trials to evaluate its effectiveness and safety in treating this condition.

How BIIB122 Works

BIIB122 is designed to target a specific protein in the body called LRRK2 (leucine-rich repeat kinase 2)^[2]. Some people with Parkinson’s disease have mutations in the LRRK2 gene, which can lead to an overactive LRRK2 protein. This overactivity is thought to contribute to the development of Parkinson’s disease. BIIB122 works by inhibiting or reducing the activity of the LRRK2 protein, potentially slowing down the progression of the disease.

Clinical Trials

Two main clinical trials are currently investigating BIIB122:

1. LUMA Study (283PD201): This is a Phase 2b trial studying the effectiveness and safety of BIIB122 in people with Parkinson’s disease^[1]. It involves participants taking either BIIB122 or a placebo (a pill with no active ingredient) for up to 144 weeks. The main goal is to see if BIIB122 can slow down the worsening of Parkinson’s symptoms.

2. LRRK2-PD Study: This is a Phase 2a trial specifically looking at people with Parkinson’s disease who have a mutation in the LRRK2 gene^[2]. It aims to evaluate the safety of BIIB122 and how well it engages with its target (the LRRK2 protein) in these patients.

Eligibility Criteria

To participate in these trials, patients must meet certain criteria. Some key requirements include:

• Having a clinical diagnosis of Parkinson’s disease
• Being at least 30 years old
• For the LRRK2-PD study, having a confirmed LRRK2 gene mutation
• Not having other significant neurological disorders
• Not having had brain surgery for Parkinson’s disease (like deep brain stimulation)

It’s important to note that there are additional criteria, and a doctor would need to assess each individual to determine if they’re eligible for the trial^[1][2].

Potential Benefits

While it’s too early to know for certain, researchers hope that BIIB122 could offer several benefits for people with Parkinson’s disease:

• Slowing down the progression of the disease
• Improving motor symptoms (like tremors and stiffness)
• Enhancing daily living activities
• Potentially being more effective for people with LRRK2 mutations

The clinical trials are designed to measure these potential benefits using various scales and assessments^[1][2].

Safety and Side Effects

A primary goal of both clinical trials is to assess the safety of BIIB122. Researchers are carefully monitoring for any side effects or adverse events that might occur during the treatment period. This includes both minor side effects and more serious adverse events.

In the LRRK2-PD study, researchers are also looking at specific markers in the blood and urine to understand how the drug is affecting the body at a molecular level^[2]. This information will help determine if BIIB122 is working as intended and if it’s safe for long-term use.

Future Prospects

If these clinical trials show positive results, BIIB122 could potentially become a new treatment option for people with Parkinson’s disease. It’s particularly exciting for those with LRRK2 mutations, as it could be one of the first treatments specifically targeting this genetic form of the disease.

However, it’s important to remember that drug development is a long and complex process. Even if these trials are successful, it may still be several years before BIIB122 becomes widely available. In the meantime, these studies are contributing valuable knowledge to our understanding of Parkinson’s disease and how to treat it^[1][2].